Product detail

RETA

Retatrutide is a novel 39-amino-acid triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. This triple agonist approach represents a new paradigm in metabolic research. Early studies have shown remarkable effects on body weight reduction and metabolic parameters, with Phase 2 trials demonstrating unprecedented efficacy in weight management research.